Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis

References

• AntoniSFerlayJSoerjomataramIBladder cancer incidence and mortality: a global overview and recent trendsEur Urol20177119610827370177
   PubMed Web of Science ®Google Scholar
• Murta-NascimentoCSchmitz-DragerBJZeegersMPEpidemiology of urinary bladder cancer: from tumor development to patient’s deathWorld J Urol200725328529517530260
   PubMed Web of Science ®Google Scholar
• XuXWuJMaoYDiabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studiesPloS One201383e5807923472134
   PubMed Web of Science ®Google Scholar
• McConkeyDJChoiWOchoaADinneyCPIntrinsic subtypes and bladder cancer metastasisAsian J Urol20163426026729264194
   PubMed Web of Science ®Google Scholar
• SuzukiSArnoldLLPenningtonKLEffects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the ratToxicol Sci2010113234935719858066
   PubMed Web of Science ®Google Scholar
• JinSMSongSOJungCHRisk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort studyJ Korean Med Sci201429223824224550651
   PubMed Web of Science ®Google Scholar
• KuoHWTiaoMMHoSCYangCYPioglitazone use and the risk of bladder cancerKaohsiung J Med Sci2014302949724444539
   PubMed Web of Science ®Google Scholar
• LewisJDHabelLAQuesenberryCPPioglitazone use and risk of bladder cancer and other common cancers in persons with diabetesJAMA2015314326527726197187
   PubMed Web of Science ®Google Scholar
• HsiaoFYHsiehPHHuangWFTsaiYWGauCSRisk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control studyDrug Saf201336864364923797604
   PubMed Web of Science ®Google Scholar
• NeumannAWeillARicordeauPPioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort studyDiabetologia20125571953196222460763
   PubMed Web of Science ®Google Scholar
• MackenzieTAZahaRSmithJKaragasMRMordenNEDiabetes pharmacotherapies and bladder cancer: a medicare epidemiologic studyDiabetes Ther201671617326894755
   PubMed Web of Science ®Google Scholar
• VallarinoCPerezAFuscoGComparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weightsClin Drug Investig2013339621631
   PubMed Web of Science ®Google Scholar
• AzoulayLYinHFilionKBThe use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control studyBMJ2012344e364522653981
   PubMed Web of Science ®Google Scholar
• WeiLMacDonaldTMMackenzieISPioglitazone and bladder cancer: a propensity score matched cohort studyBr J Clin Pharmacol201375125425922574756
   PubMed Web of Science ®Google Scholar
• KorhonenPHeintjesEMWilliamsRPioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countriesBMJ2016354i390327530399
   PubMed Web of Science ®Google Scholar
• LeeMYHsiaoPJYangYHLinKDShinSJThe association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney diseasePloS One201491e8547924427312
   PubMed Web of Science ®Google Scholar
• BalajiVSeshiahVAshtalakshmiGRamananSGJanarthinakaniMA retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian populationIndian J Endocrinol Metab201418342542724944944
   PubMedGoogle Scholar
• GuptaSGuptaKRaviRPioglitazone and the risk of bladder cancer: an Indian retrospective cohort studyIndian J Endocrinol Metab201519563964326425474
   PubMedGoogle Scholar
• LevinDBellSSundRPioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysisDiabetologia201558349350425481707
   PubMed Web of Science ®Google Scholar
• FujimotoKHamamotoYHonjoSPossible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetesDiabetes Res Clin Pract2013992e212323228390
   PubMed Web of Science ®Google Scholar
• SongSOKimKJLeeBWThe risk of bladder cancer in korean diabetic subjects treated with pioglitazoneDiabetes Metab J201236537137823130322
   PubMedGoogle Scholar
• TsengCHPioglitazone and bladder cancer: a population-based study of TaiwaneseDiabetes Care201235227828022210574
   PubMed Web of Science ®Google Scholar
• TuccoriMFilionKBYinHPioglitazone use and risk of bladder cancer: population based cohort studyBMJ2016352i154127029385
   PubMed Web of Science ®Google Scholar
• HanEJangSYKimGRosiglitazone use and the risk of bladder cancer in patients with type 2 diabetesMedicine (Baltimore)2016956e278626871835
   PubMed Web of Science ®Google Scholar
• GarryEMBuseJBLundJLPateVSturmerTComparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetesDiabetes Obes Metab201820112914028661561
   PubMed Web of Science ®Google Scholar
• ErdmannEHardingSLamHPerezATen-year observational followup of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetesDiabetes Obes Metab201618326627326592506
   PubMed Web of Science ®Google Scholar
• VaccaroOMasulliMNicolucciAEffects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trialLancet Diabetes Endocrinol201751188789728917544
   PubMed Web of Science ®Google Scholar
• fda.gov [homepage on the Internet]FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancerUS Food and Drug Administration2016 Available from: https://www.fda.gov/Drugs/DrugSafety/ucm519616Accessed May 2, 2018
   Google Scholar
• DavidsonMBPanDAn updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitisDiabetes Res Clin Pract201713510211029146119
   PubMed Web of Science ®Google Scholar
• FilipovaEUzunovaKKalinovKVekovTPioglitazone and the risk of bladder cancer: a meta-analysisDiabetes Ther20178470572628623552
   PubMed Web of Science ®Google Scholar
• PaiSAKshirsagarNAPioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: a systematic review & comparison with European Medicines Agency Assessment ReportIndian J Med Res20161445671680
   Google Scholar
• TurnerRMKwokCSChen-TurnerCThiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysisBr J Clin Pharmacol201478225827324325197
   PubMed Web of Science ®Google Scholar
• HeSTangYHZhaoGPioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysisTumor Biol201435320952102
   PubMedGoogle Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementAnn Intern Med2009151426426919622511
   PubMed Web of Science ®Google Scholar
• Ottawa Hospital Research Institute [homepage on the Internet]WellsGASheaBO’ConnellDOThe Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAccessed May 2, 2018
   Google Scholar
• HigginsJPGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.10 [updated32011The Cochrane Collaboration2011 Available from: http://handbookAccessed May 2, 2018
   Google Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• ZengDLinDYOn random-effects meta-analysisBiometrika2015102228129426688589
   PubMed Web of Science ®Google Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• HsuYHYangYTChenPNAssociation between pioglitazone and bladder cancer among patients with type II diabetes: a propensity score matched cohort studyValue in Health2014173A73
   Web of Science ®Google Scholar
• PiccinniCMotolaDMarchesiniGPoluzziEAssessing the association of pioglitazone use and bladder cancer through drug adverse event reportingDiabetes Care20113461369137121515844
   PubMed Web of Science ®Google Scholar
• LinHCHsuYTKachingweBHDose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort studyJ Clin Pharm Ther201439435436024661226
   PubMed Web of Science ®Google Scholar
• KaoCHSunLMChenPCA population-based cohort study in Taiwan–use of insulin sensitizers can decrease cancer risk in diabetic patients?Ann Oncol201324252353023110810
   PubMed Web of Science ®Google Scholar
• MamtaniRHaynesKBilkerWBAssociation between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort studyJ Natl Cancer Inst2012104181411142122878886
   PubMedGoogle Scholar
• BazelierMTde VriesFVestergaardPLeufkensHGDe BruinMLUse of thiazolidinediones and risk of bladder cancer: disease or drugs?Curr Drug Saf20138536437024215315
   PubMedGoogle Scholar
• KernanWNViscoliCMFurieKLPioglitazone after ischemic stroke or transient ischemic attackN Engl J Med2016374141321133126886418
   PubMed Web of Science ®Google Scholar
• ChingJAmiridisSStylliSSThe peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cellsOncotarget2015625213012131426046374
   PubMedGoogle Scholar
• WangYTanHXuDThe combinatory effects of PPAR-gamma agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cellsInt J Mol Med201434126226824820432
   PubMed Web of Science ®Google Scholar
• LangleYLodillinskyCBelgoroskyDSandesEOEijanAMRole of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guerin bladder cancer therapyJ Urol201218862384239023088980
   PubMed Web of Science ®Google Scholar
• VarleyCLSouthgateJEffects of PPAR agonists on proliferation and differentiation in human urotheliumExp Toxicol Pathol200860643544118571911
   PubMedGoogle Scholar
• YangDRLinSJDingXFHigher expression of peroxisome proliferator-activated receptor gamma or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasionUrology20138151109.e1623522297
   PubMed Web of Science ®Google Scholar
• LewisJDHabelLQuesenberryCProteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancerPharmacoepidemiol Drug Saf201423663664524764283
   PubMed Web of Science ®Google Scholar